Results
|
21.
|
|
|
22.
|
|
|
23.
|
|
|
24.
|
|
|
25.
|
|
|
26.
|
|
|
27.
|
|
|
28.
|
|
|
29.
|
|
|
30.
|
Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer. [electronic resource] by
- Dittrich, C
- Coudert, B
- Paz-Ares, L
- Caponigro, F
- Salzberg, M
- Gamucci, T
- Paoletti, X
- Hermans, C
- Lacombe, D
- Fumoleau, P
Producer: 20030428
In:
European journal of cancer (Oxford, England : 1990) vol. 39
Availability: No items available.
|
|
31.
|
|
|
32.
|
A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas. [electronic resource] by
- Fiedler, W
- DeDosso, S
- Cresta, S
- Weidmann, J
- Tessari, A
- Salzberg, M
- Dietrich, B
- Baumeister, H
- Goletz, S
- Gianni, L
- Sessa, C
Producer: 20170721
In:
European journal of cancer (Oxford, England : 1990) vol. 63
Availability: No items available.
|
|
33.
|
|